JAGX
Jaguar Health, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.60
−14.06%Aug 26, 2026, 13:00 UTC
Jaguar Health initiated the commercial launch of Neonorm Dog, a non-prescription plant-based product for dogs, and plans to make it available through Amazon and Chewy soon.
Source:Aug 19, 2026, 00:00 UTC
Jaguar Health reported Q2 2026 revenue of $1.225 million, down 59% year-over-year, with a net loss of $12.69 million and diluted EPS of -$15.68.
Source:Aug 5, 2026, 13:00 UTC
Jaguar Health satisfied the conditions to receive a $2 million holdback payment from Future Pak under its U.S. commercial licensing agreement for Mytesi and Canalevia-CA1.
Source:Jul 22, 2026, 13:00 UTC
Jaguar Health's subsidiary Napo Pharmaceuticals is providing crofelemer powder for oral solution to an additional infant patient in the European Union for compassionate use treatment of intestinal failure due to microvillus inclusion disease.
Jun 25, 2026, 00:00 UTC
Jaguar Health and its subsidiary Napo Pharmaceuticals amended their Manufacturing and Supply Agreement with Woodward Specialty LLC, clarifying inventory title transfer rules and establishing a temporary inventory management arrangement.
Jun 22, 2026, 13:00 UTC
Jaguar Health's Board of Directors initiated a process to explore strategic alternatives to maximize stockholder value, aligned with its planned NDA filing for a rare disease intestinal failure program.
Source:Jun 11, 2026, 00:00 UTC
Jaguar Health, Inc. signed a $40 million common stock equity line of credit (ELOC) offering agreement with C/M Capital Partners, LP on June 9, 2026.
Jun 2, 2026, 00:00 UTC
Jaguar Health, Inc. issued 31,958 shares of common stock to Streeterville Capital, LLC in exchange for 3.72 outstanding shares of Series Q Perpetual Preferred Stock on May 26, 2026.